William Blair Investment Management LLC Has $93.48 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

William Blair Investment Management LLC trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,241,547 shares of the company's stock after selling 105,451 shares during the period. William Blair Investment Management LLC owned approximately 0.37% of Teva Pharmaceutical Industries worth $93,483,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Smithfield Trust Co grew its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $66,000. IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $104,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 0.4 %

NYSE TEVA traded down $0.07 during trading hours on Friday, hitting $16.18. 9,418,773 shares of the company traded hands, compared to its average volume of 12,611,027. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business's 50-day moving average is $17.88 and its 200-day moving average is $18.23. The stock has a market capitalization of $18.34 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TEVA. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Finally, Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.